Healthcare Needs and Illness Experience in Children With Rare Genetic and Metabolic Diseases (TD/MPP_1)

November 16, 2026 updated by: Fondazione IRCCS San Gerardo dei Tintori

This prospective observational study aims to describe and characterize the multidimensional care needs of children and adolescents aged 1 month to 18 years with rare genetic and metabolic diseases, with particular emphasis on the identification of pediatric palliative care needs.

The study seeks to answer the question of which clinical, physical, psychological, social, and care-related needs characterize this population, and to what extent these needs are associated with complex care requirements and potential eligibility for pediatric palliative care.

Additional objectives include assessing pain, sleep disturbances, psychological well-being, quality of life, physical and social functioning, medication-related adverse events, symptom interference with daily life, and caregiver burden. The study will also explore individual care needs and the transition from pediatric to adult healthcare services.

A subgroup of approximately 150 participants will undergo longitudinal assessments every three months for up to 12 months to describe changes in care needs over time and identify factors potentially associated with worsening clinical and care complexity. Furthermore, a qualitative substudy involving caregivers and adolescents will explore the lived experience of illness and the meaning attributed to the disease by children and their families through semi-structured interviews.

Overall, the study aims to provide a comprehensive understanding of the care needs and illness experience of children with rare genetic and metabolic diseases, supporting the early identification of complex needs and the development of more personalized, proactive, and family-centered care pathways.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Italy
      • Monza, Italy, Italy, 20900
        • Fondazione IRCCS San Gerardo dei Tintori

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 18 years (Child, Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study participants will be consecutively recruited from the outpatient clinics of Metabolic Diseases and Clinical Genetics at Fondazione IRCCS San Gerardo dei Tintori, a tertiary referral hospital located in Monza, Italy. The study population will include patients attending these clinics for specialist assessment and follow-up. For the qualitative substudy, caregivers and eligible adolescent patients will be selected from the same clinical population.

Description

Inclusion Criteria:

  • Participants aged between 1 month and 18 years.
  • Diagnosis of a rare genetic or metabolic disease.
  • Written informed consent freely provided by the parents and/or legal guardians and obtained before study participation.

Exclusion Criteria:

  • Diagnosis of trisomy 21 (Down syndrome).
  • Unavailability of cultural mediators or language interpreters during the information and informed consent process, as well as during the assessment of patients or caregivers with limited or no understanding of the Italian language.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AccaPed Total Score for the Assessment of Complex Pediatric Palliative Care Needs
Time Frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

The total score of the AccaPed scale will be used to assess complex pediatric palliative care needs. The assessment will be performed at study enrollment in all participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to describe changes in care needs over time.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Paediatric Palliative Care Needs
Time Frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

The Paediatric Palliative Screening Scale (PaPaS) will be used to assess pediatric palliative care needs in participants aged 1 to 18 years. The assessment will be performed at study enrollment in all eligible participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to evaluate changes in palliative care needs over time.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Intensity Assessment
Time Frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pain intensity will be assessed using age- and cognitive status-appropriate validated tools: the Revised Face, Legs, Activity, Cry, Consolability scale (r-FLACC), the Face, Legs, Activity, Cry, Consolability scale (FLACC), the Wong-Baker FACES Pain Rating Scale, or the Numeric Rating Scale (NRS). The most appropriate instrument will be selected according to the participant's age and cognitive status. The assessment will be performed at study enrollment in all eligible participants and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Assessment of Nociceptive Pain Phenotype
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants, where applicable.

The nociceptive pain phenotype will be characterized through the assessment of central and peripheral sensitization using simplified Quantitative Sensory Testing (QST), the identification of nociplastic pain according to the definition of the International Association for the Study of Pain (IASP), and the assessment of neuropathic pain using the PainDETECT Questionnaire (PD-Q). The assessment tools will be selected according to the participant's age and cognitive status. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months, where applicable.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants, where applicable.
Sleep Disturbances Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Sleep disturbances will be assessed using the Sleep Disturbance Scale for Children (SDSC) in participants aged 6 months to 18 years. The questionnaire will be completed by the researcher or caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Psychological Well-being Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Psychological aspects will be assessed using the Revised Children's Anxiety and Depression Scale (RCADS) in participants aged 8 to 18 years. The questionnaire will be completed by the researcher, caregiver, or participant, as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Catastrophizing Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pain catastrophizing will be assessed using the Pain Catastrophizing Scale for Children (PCS-C) in participants aged 8 to 18 years. The questionnaire will be completed by the participant. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Health-Related Quality of Life Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL) in participants aged 2 to 18 years. The appropriate version will be selected according to age, with the possibility of using the parent-proxy form for participants unable to complete the questionnaire because of age or cognitive impairment. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Physical Function Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Physical function will be assessed using the Gross Motor Function Classification System (GMFCS) in participants aged 1 to 18 years and the Function Disability Inventory (FDI) in participants aged 8 to 18 years. The FDI parent-report version may be used when required for children with cognitive difficulties. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Social Function Assessment
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Social function will be assessed using the KIDSCREEN-27 in participants aged 8 to 18 years, using the self-report or parent-proxy version as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pharmacological Treatment, Perceived Benefit, and Adverse Events
Time Frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pharmacological treatment will be characterized by recording the number and type of medications taken, the perceived benefit of treatment, and any reported medication-related adverse events. Treatment-related changes will also be assessed using the Patient Global Impression of Change (PGIC) in participants aged 8 to 18 years and the Observer Global Impression of Change (OGIC) parent-proxy form in participants with cognitive impairment. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Symptom Interference with Daily Life
Time Frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

The impact of symptoms on daily life will be assessed using the Symptom Screening in Pediatrics Tool (SSPedi). The self-report version will be used in participants aged 8 to 18 years, while the parent-proxy version will be used in participants aged 2 to 18 years, according to the participant's ability to complete the questionnaire. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Caregiver Burden Assessment
Time Frame: At study enrollment for all participants with an eligible caregiver assessment; every three months for 12 months in a subgroup of approximately 150 participants.

Caregiver burden will be assessed using the Caregiver Burden Inventory (CBI), completed by the caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants with an eligible caregiver assessment; every three months for 12 months in a subgroup of approximately 150 participants.
Transition to Adult Healthcare Services
Time Frame: During the 36-month study period.

The transition to adult healthcare services will be assessed by recording the proportion of patients requiring transfer to adult care, the proportion of patients for whom the transfer process has been initiated by 17 years and 6 months of age, and the proportion of patients effectively transferred to adult healthcare services upon reaching 18 years of age.

During the 36-month study period.
Individual Nursing Care Needs Classified According to ICNP
Time Frame: At baseline; repeated every three months for 12 months in a subgroup of approximately 150 participants

Individual care needs will be identified and classified using the International Classification for Nursing Practice (ICNP), a standardized terminology for describing and documenting nursing practice. The assessment will support the systematic description of participants' individual nursing care needs.

At baseline; repeated every three months for 12 months in a subgroup of approximately 150 participants
Illness Experience and Meaning Attributed to the Disease by Children and Families
Time Frame: Until data saturation is achieved during the study period.

The illness experience and the meaning attributed to the disease by children and their families will be explored through semi-structured interviews involving a subgroup of caregivers and adolescent participants aged 12 years or older. Interviews will be conducted until data saturation is achieved. The qualitative data will be analyzed to identify relevant themes concerning illness experience and care.

Until data saturation is achieved during the study period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2029

Study Completion (Estimated)

November 1, 2029

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TD/MPP_1
  • 7408 (Other Identifier: Comitato Etico Territoriale Lombardia 3 (Territorial Ethics Committee Lombardy 3))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.